Related Experiment Videos
Oxycodone controlled release in cancer pain management.
1Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Rozzano (MI), Italy.
Therapeutics and Clinical Risk Management
|March 25, 2008
Summary
Oxycodone offers comparable pain relief to morphine for moderate to severe cancer pain, with potentially fewer side effects. This makes oxycodone a viable first-line treatment option for managing chronic cancer pain.
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Morphine is the WHO-recommended opioid for moderate to severe cancer pain due to availability and cost, not proven superiority.
- Patients may require alternative opioids or routes for inadequate pain relief or side effects.
- Opioid rotation can improve pain control and reduce adverse effects.
Purpose of the Study:
- To evaluate oxycodone as an alternative to morphine for moderate to severe cancer pain.
- To compare the efficacy and toxicity profiles of oxycodone and morphine.
Main Methods:
- Review of studies comparing controlled-release oxycodone with morphine, immediate-release oxycodone, and hydromorphone.
- Pharmacokinetic analysis of oxycodone, including bioavailability and half-life.
- Assessment of adverse effect profiles, particularly central nervous system side effects.
Main Results:
- Controlled-release oxycodone demonstrates efficacy comparable to morphine, immediate-release oxycodone, and hydromorphone.
- Oxycodone exhibits higher oral bioavailability (>60%) than morphine (20%).
- Oxycodone appears to have a better toxicity profile than morphine, with a lower incidence of central nervous system side effects.
Conclusions:
- Oxycodone is a valid alternative to morphine for managing moderate to severe cancer pain.
- Oxycodone can be considered as a first-line treatment option.
- Opioid rotation to oxycodone may improve pain management and tolerability.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...